WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC lead to specific immune responses in AML patients and have an impact on progression free survival

      Age or co-morbidity factors reduce therapy options in patients diagnosed with acute myeloid leukemia (AML). We treated 5 AML patients in morphological remission after incomplete induction/consolidation chemotherapy with dendritic cells (DCs) targeting WT-1 and PRAME. DCs were produced using a maturation cocktail containing the TLR 7/8 ligand R848. DCs showed a polarized release of IL-12p70 combined with low IL-10.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect